Langzeitergebnisse in der Behandlung der Endometriose mit dem GnRH-Agonisten Nafarelinacetat (Synarela®)

This long-term follow-up study evaluated 21 patients with histologically confirmed endometriosis who received a three-phase treatment with the GnRH agonist nafarelin acetate (Synarela) in 1992–1993, assessing recurrence status and fertility outcomes a median of 96 months later. Recurrence was defined as renewed endometriosis-associated pain symptoms, and clinical assessment plus interviews were used to characterize symptom and quality-of-life changes. During follow-up, 18/21 reported recurrent symptoms, with 14 experiencing recurrence within the first year, and recurrence was not associated with rAFS scores; repeat endometriosis treatments were needed in 10 women, though 61% reported moderate-to-significant improvement in quality of life. Fertility outcomes were comparatively favorable, with 9/13 women with an unfulfilled desire for children achieving pregnancy (87.5% spontaneous) and 12 births from 16 pregnancies. This paper is centrally about endometriosis — it reports long-term outcomes of nafarelin acetate treatment, including recurrence and fertility results.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works